First US Patient Receives Patient-Derived Implant to Treat a Leading Vision Loss Cause

August 31, 2022 by Dan McCue
First US Patient Receives Patient-Derived Implant to Treat a Leading Vision Loss Cause
Left shows an image of the full-RPE-patch (2 x 4 mm). Each dot is an RPE cell with the borders stained green. Each patch contains approximately 75,000 RPE cells. Right image shows patch RPE cells at higher magnification. Kapil Bharti, Ph.D., NEI

WASHINGTON — A surgical team at the National Institutes of Health has successfully implanted a patch of tissue made from the patient’s own cells to treat advanced “dry” age-related macular degeneration, a leading cause of vision loss among older Americans.

Currently dry AMD, also known as geographic atrophy, has no known treatment.

In a release, the NIH said the unnamed patient received the therapy as part of a clinical trial that is the first in the United States to use replacement tissues from patient-derived induced pluripotent stem cells.

The surgery, the culmination of 10 years of research and development, was performed by Dr. Amir Kashani, Ph.D., associate professor of ophthalmology at the Wilmer Eye Institute at Johns Hopkins School of Medicine with assistance by Dr. Shilpa Kodati, a staff clinician at the National Eye Institute. 

Prior to the procedure, the patient’s blood cells were converted to iPS cells in a National Institutes of Health lab. Once converted to iPS cells, the blood can become almost any type of cell in the body.

In this case, they were programmed to become retinal pigment epithelial cells, the type of cell that degenerates in the advanced forms of dry AMD.

RPE cells nourish and support light-sensing photoreceptors in the retina. In AMD, the loss of RPE leads to the loss of photoreceptors, which causes vision loss.

The procedure was performed at the NIH Clinical Center in Bethesda, Maryland, under a phase 1/2a clinical trial to determine the therapy’s safety.

This iPS cell-derived therapy was developed by the Ocular and Stem Cell Translational Research Section team led by Kapil Bharti, Ph.D., senior investigator at the National Eye Institute, in collaboration with FUJIFILM Cellular Dynamics Inc., and Opsis Therapeutics, based in Madison, Wisconsin.

The safety and efficacy of the cell therapy was tested by the NEI preclinical team. Clinical-grade manufacturing of this cell therapy was performed at the Center for Cellular Engineering, Department of Transfusion Medicine, Clinical Center, at the National Institutes of Health.

This work was supported by the NIH Common Fund and NEI Intramural funding.

Dan can be reached at [email protected] and @DanMcCue

A+
a-
  • dry age-related macular degeneration
  • experimental surgery
  • National Institutes of Health
  • vision loss
  • In The News

    Health

    Voting

    Health

    What Do Weight Loss Drugs Mean for a Diet Industry Built on Eating Less and Exercising More?

    NEW YORK (AP) — Ever since college, Brad Jobling struggled with his weight, fluctuating between a low of 155 pounds... Read More

    NEW YORK (AP) — Ever since college, Brad Jobling struggled with his weight, fluctuating between a low of 155 pounds when he was in his 30s to as high as 220. He spent a decade tracking calories on WeightWatchers, but the pounds he dropped always crept... Read More

    April 24, 2024
    by Dan McCue
    First Lady Jill Biden Salutes ‘The Power of Research’ at DC Symposium

    WASHINGTON — Even years after the fact, First Lady Dr. Jill Biden recalled the moment with a sense of astonished... Read More

    WASHINGTON — Even years after the fact, First Lady Dr. Jill Biden recalled the moment with a sense of astonished disbelief. Biden was second lady, the wife of Vice President Joe Biden, at the time, and Maria Shriver was the first lady of California.  Both were... Read More

    April 24, 2024
    by Dan McCue
    FDA Approves New Treatment for Urinary Tract Infections

    WASHINGTON — The Food and Drug Administration approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary... Read More

    WASHINGTON — The Food and Drug Administration approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections.  “Uncomplicated UTIs are a very common condition impacting women and one of the most frequent reasons for antibiotic use,” said Dr. Peter Kim, M.S.,... Read More

    When Red-Hot Isn't Enough: New Heat Risk Tool Sets Magenta as Most Dangerous Level

    WASHINGTON (AP) — Forget about red hot. A new color-coded heat warning system relies on magenta to alert Americans to... Read More

    WASHINGTON (AP) — Forget about red hot. A new color-coded heat warning system relies on magenta to alert Americans to the most dangerous conditions they may see this summer. The National Weather Service and the Centers for Disease Control and Prevention on Monday — Earth Day... Read More

    April 23, 2024
    by Dan McCue
    President Lays Out New Steps for Protecting Nation’s Waters

    WASHINGTON — The Biden administration on Tuesday set out a new national goal for conserving and restoring the United States’... Read More

    WASHINGTON — The Biden administration on Tuesday set out a new national goal for conserving and restoring the United States’ freshwater resources, including 8 million acres of wetlands and 100,000 miles of rivers and streams. Officials unveiled the plan as state, tribal and local leaders from... Read More

    April 23, 2024
    by Beth McCue
    Study Finds Next-Gen Antibiotics Underutilized

    WASHINGTON — A new study conducted by researchers at the National Institutes of Health found clinicians frequently continue to treat... Read More

    WASHINGTON — A new study conducted by researchers at the National Institutes of Health found clinicians frequently continue to treat antibiotic-resistant infections with older generic antibiotics considered to be less effective and less safe than newer ones. Researchers examined the factors influencing doctors’ preference for older... Read More

    News From The Well
    scroll top